Benserazide (MADOPAR HBS 125 levodopa 100 mg and benserazide 25 mg capsule bottle)
Benserazide risk profile, scheduling, and guidance for claims professionals and care workers . Also known as MADOPAR HBS 125 levodopa 100 mg and benserazide 25 mg capsule bottle, MADOPAR 250 levodopa 200 mg and benserazide 50 mg tablet bottle, MADOPAR RAPID 62.5 levodopa 50 mg and benserazide 12.5 mg dispersible tablet bottle.
Benserazide (brand names: MADOPAR HBS 125 levodopa 100 mg and benserazide 25 mg capsule bottle, MADOPAR 250 levodopa 200 mg and benserazide 50 mg tablet bottle, MADOPAR RAPID 62.5 levodopa 50 mg and benserazide 12.5 mg dispersible tablet bottle) is classified as Low risk (1 risk points) by AllMeds. It is a S4 medication under the TGA in Australia. Aromatic amino acid decarboxylase inhibitor used with levodopa for Parkinson's disease, minimal workplace risk.
Key Takeaways
- TGA Schedule: S4 in Australia
- Risk level: Low (1 points)
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | S4 | Not PBS listed |
Risk Profile
Aromatic amino acid decarboxylase inhibitor used with levodopa for Parkinson's disease, minimal workplace risk.
Regulatory and Compliance Guidance
When Benserazide appears on a claimant's medication list, claims professionals should assess whether the prescribing is appropriate for the compensable injury, whether the duration is within guidelines, and whether there are interactions with other medications on the claim.
Australia TGA / PBS / State Schemes
Classified as S4 under the Therapeutic Goods Administration (TGA).
Need to assess this medication across your caseload?
Run a full risk assessment including Benserazide interactions and compliance checks.
AllMeds gives you instant risk assessments, compliance checks, and automated letters for every medication on a claim.
No credit card required. No signup for your first 2 questions.
Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.